Evaluation of AHB-137 Injection Compared to Placebo in Adults Aged 18 to 65 With Chronic Hepatitis B

What this Trial Is About

Researchers are evaluating the effectiveness and safety of AHB-137 injection in adults aged 18 to 65 with chronic hepatitis B who have not previously received treatment. This randomized, double-blind, placebo-controlled, multicenter phase 2 study aims to compare AHB-137 with a placebo to better understand its impact on the disease. Participants will receive either AHB-137 or a placebo through subcutaneous injections. The study involves monitoring viral markers such as HBV DNA and HBsAg levels during and after treatment. The treatment period and follow-up last up to 48 weeks, during which multiple virological, serological, and safety assessments will be conducted. Throughout the study, participants will undergo regular evaluations including laboratory tests for viral load and liver function, measurement of quality of life, and monitoring for adverse events. The researchers will track the proportion of participants achieving certain virological milestones and seroconversion rates. Safety assessments and drug concentration measurements will also be performed. The total participation duration extends through treatment and post-treatment observation up to 48 weeks.

A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B